# A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

> **NCT07464314** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 225 (estimated)

## Conditions studied

- Influenza, Human+COVID-19

## Interventions

- **BIOLOGICAL:** Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- **BIOLOGICAL:** Licensed Seasonal Influenza Vaccine
- **BIOLOGICAL:** Licensed COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT07464314
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-12-03
- **Final completion:** 2027-06-03
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464314, "A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07464314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*